AVBP Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into ArriVent BioPharma (AVBP)
NEW YORK CITY, NY / ACCESS Newswire / October 8, 2026 / Shareholders of ArriVent BioPharma (NASDAQ:AVBP) saw between 50% and 63% of their investment's value disappear today, October 6, 2026, after the Company announced that its global Phase 3 FURVENT trial of firmonertinib did not meet its primary endpoint. If you owned AVBP shares going into this morning's announcement and lost money, you may have legal rights whether you sold today or are still holding. AVBP shareholders who suffered losses are encouraged to submit their AVBP loss details now. You may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
FURVENT measured progression-free survival by blinded independent central review in previously untreated patients with EGFR exon 20 insertion-mutated non-small cell lung cancer. ArriVent reported some secondary-endpoint benefits and no new safety signals, but the trial did not meet its primary endpoint. Firmonertinib is the Company's lead clinical candidate.
Levi & Korsinsky has opened an investigation into potential securities law violations related to the FURVENT program on behalf of affected ArriVent shareholders. Investors who bought AVBP and sold at a loss today may be eligible to participate, and so may those still holding shares. There is no upfront cost to have your losses evaluated, and no minimum loss amount is required.
If today's FURVENT announcement cost you money, report your ArriVent investment losses here or call (212) 363-7500.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the AVBP Investigation
Q: Which statements are being investigated as potentially misleading?
A: The investigation concerns whether ArriVent BioPharma made materially false or misleading statements regarding the status and prospects of its Phase 3 FURVENT trial of firmonertinib. When the Company disclosed on October 6, 2026 that FURVENT did not meet its primary endpoint, the stock price declined sharply.
Q: When did ArriVent BioPharma allegedly mislead investors?
A: The investigation concerns statements made before the October 6, 2026 FURVENT announcement that allegedly caused investors to purchase securities at inflated prices.
Q: Who is eligible to participate in the AVBP investigation?
A: Investors who purchased AVBP stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.
Q: What do AVBP investors need to do right now?
A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.
Q: What documents do I need to participate?
A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.
Q: What if I already sold my AVBP shares -- can I still recover losses?
A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought AVBP and sold at a loss may still participate in the investigation.
Q: What if my AVBP losses are small -- is it still worth contacting a lawyer?
A: Yes. There is no minimum loss amount required to participate in the investigation.
Q: What does it cost me to participate?
A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.
Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
SOURCE: Levi & Korsinsky, LLP